November 12, 2015
Journal of Clinical Pathways Viewpoints
By Roger Longman
Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of resistance from drug companies and payers, stakeholders are finding other tools to help identify the appropriate choices.
